Search
for
Sort by
Research 91–120 of 99
- Targeting the Warburg Effect in Anaplastic Thyroid Carcinoma: Metabolic Vulnerabilities and Therapeutic Opportunities
- Aberrant Activation of the Hedgehog Pathway in Cutaneous Melanoma: Therapeutic Potential of Pharmacological Inhibitors
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- Re‐Innovation in Clinical Trial Designs Based on Precision Therapy
- Poster Presentations at the 28th Joint Meeting of the International Society of Dermatopathology, March 5–6, 2025, Orlando, Florida, USA
- Selected abstracts from the 47th meeting of the Irish Endocrine Society Sligo, 24th & 25th November 2023
- Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies
- Editor's evaluation: Crosstalk with keratinocytes causes GNAQ oncogene specificity in melanoma
- Reexamining the Role of Diet in Dermatology
- BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer
- A cross-sectional study of clinical, dermoscopic, histopathological, and molecular patterns of scalp melanoma in patients with or without androgenetic alopecia
- RASopathic Skin Eruptions during Vemurafenib Therapy
- Hair(y) Matters in Melanoma Biology
- At the Root: Cutaneous Langerhans Cell Histiocytosis
- Lentiginous melanoma. A clinically malignant entity that histopathologically seems benign. Case study harbouring BRAF V 600R mutation
- Dyad of infantile cutaneous and thymic Langerhans cell histiocytosis: Is it rare?
- Author response: Dynamics of nevus development implicate cell cooperation in the growth arrest of transformed melanocytes
- Decision letter: Dynamics of nevus development implicate cell cooperation in the growth arrest of transformed melanocytes
- Is knowledge about the genetic and epigenetic alterations in melanoma a basis for targeted therapy?
- Primary cicatricial alopecia and inflammatory bowel disease – is there a link?
- 559 Visualization of sweat suppression following botulinum toxin A by soluble microneedle arrays
- 554 Repurposing a clinical antimalarial for the therapeutic induction of lethal ER stress targeting BRAF-kinase inhibitor-resistant malignant melanoma
- 556 α 1 -AR agonist induced piloerection protects against the development of traction alopecia
- 557 A peptide derivative with known anti-wrinkle properties was identified as potent dipeptiylpeptidase-4 inhibitor
- The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
- Management of Toxicities of Targeted Therapies
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- Using morphological operators and inpainting for hair removal in dermoscopic images
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy